What significant box warning is associated with Irbesartan?

Irbesartan is an angiotensin II receptor antagonist commonly used for the treatment of hypertension and diabetic nephropathy. The significant box warning associated with Irbesartan pertains to the risks associated with its use during pregnancy. Specifically, the medication is known to cause serious harm or death to the developing fetus when administered to pregnant women, especially during the second and third trimesters. This warning is crucial because it highlights the potential teratogenic effects of the drug, emphasizing the importance of avoiding its use in pregnant individuals and providing warnings for women of childbearing age.

Other options, although they may represent important considerations in pharmacotherapy, do not carry the same level of risk that necessitates a black box warning. For instance, while breastfeeding caution is important, the primary concern regarding the use of Irbesartan revolves around its impact during pregnancy.